よむ、つかう、まなぶ。
会議資料 (201 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00046.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；III➀-73
の PDQ®引用文献番号 32）
12) Dourthe ME, Phulpin A, Auperin A, et al. Rituximab in addition to LMB-based chemotherapy
regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of
the French LMB2001 prospective study. Haematologica 2022; 107(9): 2173-2182.（米国 NCCN
の診療ガイドライン引用文献番号 122）
13) Dourthe ME, Auperin A, Rigaud C, et al. Excellent outcome of children/adolescents with primary
mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with
rituximab. Haematologica 2024; 109(11): 3790-3794.（米国 NCCN の診療ガイドライン引用
文献番号 123）
14) Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in children and adolescents
with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's
Oncology Group report. Br J Haematol 2013; 162(5): 678-683.（米国国立がん研究所の PDQ®
引用文献番号 30）
15) Alexander S, Aupérin A, Bomken S, et al. Effect of rituximab on immune status in children with
mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL
Ritux 2010 trial. Lancet Haematol 2023; 10(6): e445-e457.（米国国立がん研究所の PDQ®引用
文献番号 33）
16) Bhuller K, Bomken S, Burke A, et al. Guideline for management of mature B-cell non-Hodgkin
lymphoma (Final Version March 2020). CCLG NHL Special Interest Group & Paediatric
Oncology Pharmacy Group.
17) European standard clinical practice recommendations for non-hodgkin lymphoma of childhood
and adolescence. (Version 1.0, 04.10.2021)
18) Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial
Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin
lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in
addition to standard LMB chemotherapy (CT) regimen. Journal of Clinical Oncology 2016;
34(15 suppl): 10507-10507. (Meeting Abstract: 2016 ASCO Annual Meeting I)
19) Jeon W, Koh YK, Kang S, et al. Clinical characteristics and treatment outcomes of children and
adolescents with aggressive mature B-cell lymphoma: a single-center analysis. Blood Res 2022;
57(1): 41-50.
20) 臨床研究等提出・公開システム. Available from: https://jrct.mhlw.go.jp/latest-detail/
jRCTs041180089 [Cited 2025 May 7]
21) Mori T, Osumi T, Kada A, et al. Rituximab with standard LMB chemotherapy in pediatric
high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. Eur J
Haematol 2024; 112(4): 585-593.
22) Sheikh IN, Elgehiny A, Ragoonanan D, et al. Management of Aggressive Non-Hodgkin
Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric
65
201/370
の PDQ®引用文献番号 32）
12) Dourthe ME, Phulpin A, Auperin A, et al. Rituximab in addition to LMB-based chemotherapy
regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of
the French LMB2001 prospective study. Haematologica 2022; 107(9): 2173-2182.（米国 NCCN
の診療ガイドライン引用文献番号 122）
13) Dourthe ME, Auperin A, Rigaud C, et al. Excellent outcome of children/adolescents with primary
mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with
rituximab. Haematologica 2024; 109(11): 3790-3794.（米国 NCCN の診療ガイドライン引用
文献番号 123）
14) Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in children and adolescents
with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's
Oncology Group report. Br J Haematol 2013; 162(5): 678-683.（米国国立がん研究所の PDQ®
引用文献番号 30）
15) Alexander S, Aupérin A, Bomken S, et al. Effect of rituximab on immune status in children with
mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL
Ritux 2010 trial. Lancet Haematol 2023; 10(6): e445-e457.（米国国立がん研究所の PDQ®引用
文献番号 33）
16) Bhuller K, Bomken S, Burke A, et al. Guideline for management of mature B-cell non-Hodgkin
lymphoma (Final Version March 2020). CCLG NHL Special Interest Group & Paediatric
Oncology Pharmacy Group.
17) European standard clinical practice recommendations for non-hodgkin lymphoma of childhood
and adolescence. (Version 1.0, 04.10.2021)
18) Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial
Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin
lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in
addition to standard LMB chemotherapy (CT) regimen. Journal of Clinical Oncology 2016;
34(15 suppl): 10507-10507. (Meeting Abstract: 2016 ASCO Annual Meeting I)
19) Jeon W, Koh YK, Kang S, et al. Clinical characteristics and treatment outcomes of children and
adolescents with aggressive mature B-cell lymphoma: a single-center analysis. Blood Res 2022;
57(1): 41-50.
20) 臨床研究等提出・公開システム. Available from: https://jrct.mhlw.go.jp/latest-detail/
jRCTs041180089 [Cited 2025 May 7]
21) Mori T, Osumi T, Kada A, et al. Rituximab with standard LMB chemotherapy in pediatric
high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. Eur J
Haematol 2024; 112(4): 585-593.
22) Sheikh IN, Elgehiny A, Ragoonanan D, et al. Management of Aggressive Non-Hodgkin
Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric
65
201/370